tbuckley/cabot-search huggingface dataset:
B-Lymphocyte Alloantigens Associated with Systemic Lupus Erythematosus
Authors: James L. Reinertsen, John H. Klippel, Armead H. Johnson, Alfred D. Steinberg, John L. Decker, Dean L. Mann
Journal: New England Journal of Medicine (1978)

We examined B-lymphocyte alloantigens in 41 patients with systemic lupus erythematosus and 184 controls, using a panel of 47 pregnancy serums, and compared reaction frequencies of individual serums. One serum, la-715, reacted with B lymphocytes from 75.6 per cent of patients and 14.1 per cent of controls (Pc less than 0.005, relative risk 18.8). Twenty-eight of the patients were also typed with a panel of HLA-D-related serums from the Seventh International Histocompatibility Workshop, HLA-DRw types assigned, and compared to 490 Workshop controls. Both HLA-DRw2 (57.1 per cent vs. 26.4 per cent, Pc less than 0.004) and HLA-DRw3 (46.4 per cent vs. 22.2 per cent, Pc less than 0.03) were increased in systemic lupus erythematosus. This study demonstrates that select B-lymphocyte alloantigens, which are controlled by genes in the major histocompatibility complex, are present in increased frequency in systemic lupus erythematosus.
Abstract 4125: The effects of S100B on cell signaling in malignant melanoma
Authors: Kira Gianni, Paul T. Wilder, Michele I. Vitolo, Paul Shapiro, David J. Weber
Journal: Cancer Research (2010)

Abstract Establishing the mechanism by which S100B effects ERK and its downstream proteins will provide valuable insight into the role of S100B in the progression of melanoma and potentially aid in developing new pharmacological drugs. The protein S100B is an effective prognostic marker for human malignant melanoma. Increased levels of serum S100B are predictive of disease stage, increased recurrence, and low overall survival. It has previously been found that S100B directly interacts with the tumor suppressor protein p53, down-regulating its protein levels, thereby allowing damaged cells to proliferate and mutations to propagate. S100B has also been implicated in several other signaling pathways, including the MAPK pathway. The initial hypothesis tested was that S100B inhibits the phosphorylation of ERK targets in a calcium-dependent manner. The S100B binding motif has been found to overlap with the ERK binding motif, suggesting that S100B binds the targets and physically prevents ERK from interacting with and subsequently phosphorylating them. ERK kinase assays revealed that the addition of S100B in the presence of calcium decreased ERK phosphorylation of RSK, but more dramatically Elk-1. Additionally, RSK was detected in S100B pull-downs in the presence of calcium; however, it was not detected in the presence of the calcium chelator EDTA. Over-expression of normal human S100B, but not a mutant S100B incapable of binding calcium, results in decreased phosphorylated RSK at Thr573, yet increased phosphorylated ERK, interestingly. Since a rise in serum S100B levels is indicative of tumor progression, it was also of interest to see if the addition of extracellular S100B alone is sufficient to elicit the same signaling response. Preliminary data shows an increase in phosphorylated ERK after the addition of low concentrations of extracellular S100B, as well as effects on ERK targets. We demonstrate that the calcium-binding protein S100B affects the MAPK pathway by simultaneously increasing phosphorylated ERK and decreasing phosphorylated RSK and Elk-1, together which could have a significant impact on cancer progression. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 4125.
European Tamoxifen Studies Moving Ahead
Authors: C. Vanchieri
Journal: JNCI Journal of the National Cancer Institute (1993)

Journal Article European Tamoxifen Studies Moving Ahead Get access Cori Vanchieri Cori Vanchieri Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 85, Issue 18, 15 September 1993, Pages 1450–1451, https://doi.org/10.1093/jnci/85.18.1450 Published: 15 September 1993
FRI0161 Sec16a Gene Deletion in A Large Axial Spondyloarthritis Family
Authors: D.D. O'Rielly, M. Uddin, A.A. Mostafa, D. Codner, D. Hackett, N. Haroon, R. Inman, P. Rahman
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Genetic factors are of major importance in susceptibility to ankylosing spondylitis (AS). Currently there are 43 genetic loci associated with AS pathogenesis but these only explain a small proportion of the heritability which suggests that other rare genomic variants may contribute as risk factors. Given that AS is a subset of axial spondyloarthritis, it too is likely to have a strong genetic component. <h3>Objectives</h3> To identify novel rare, highly penetrant mutations associated with AxSpA segregating within well-characterized families. <h3>Methods</h3> Samples were collected from affected and healthy individuals from a large multigenerational, well-characterized family with AxSpA with Northern European Ancestry. All AxSpA patients satisfied the ASAS classification. Full exome sequencing was performed on eleven family members using the Agilent SureSelect Human All Exon kit V4 for library preparation and exome enrichment and sequencing was performed on an Illumina HiSeq 2000 instrument with TruSeq sequencing chemistry V3. Variants of interest identified by exome sequencing were confirmed using Sanger sequencing. Gene expression profiling was performed using a Taqman Gene Expression Assay (Cat#4331182, SEC16A-Hs00389570_m1, GAPDH-Hs99999905_M1) and protein expression was assessed using Western analysis using a commercial SEC16A antibody. <h3>Results</h3> Our family-based exome sequencing analysis revealed a 9-bp in-frame deletion in SEC16A which segregated with AxSpA in the family. This deletion was confirmed in extended family members with 7/9 of the clinically diagnosed AxSpA members carrying the SEC16A deletion using Sanger sequencing. All healthy (i.e., not diagnosed with AxSpA) family members did not carry the deletion. The in-frame deletion had no significant impact on gene or protein expression. <h3>Conclusions</h3> Full exome sequencing of a large multigenerational AxSpA family revealed a 9-bp deletion in SEC16A segregating in the majority of affected family members. Although this in-frame deletion had no significant impact on gene or protein expression, a detrimental impact on protein structure of SEC16A remains a possibility and is currently under investigation. The association of this deletion within the SEC16A gene with AxSpA is particularly interesting given that the gene product plays a role in protein transport from the endoplasmic reticulum (ER) to the Golgi and mediates COPII vesicle formation at the transitional ER. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.3327
FRI0565-HPR Shoulder Function is Impaired in Early Rheumatoid Arthritis- A Controlled Study
Authors: A. Bilberg, T. Bremell, I. Balogh, K. Mannerkorpi
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Patients with rheumatoid arthritis (RA) risk impaired shoulder function due to the inflammatory process. Despite improved pharmacological treatment, patients with early RA report difficulties with activities involving the shoulder. <h3>Objectives</h3> To compare shoulder function and activity limitation related to the shoulder, arm and hand in women with early RA compared to age-matched healthy women. <h3>Methods</h3> This controlled cross-sectional study included 103 women with early rheumatoid arthritis and a reference group of 103 age-matched healthy women. The mean age was 47.1 (SD 10.0) years, the mean disease duration was 20.3 (SD 8.5) months and the mean DAS28 score was 3.8 (SD 1.4) among the patients. Measurements: Shoulder function was assessed by isometric shoulder muscle strength, active shoulder-arm movement, and activity-induced shoulder pain. Hand-grip force was also recorded. Activity limitations related to the upper extremities were assessed with the Disability of the Arm, Shoulder and Hand (DASH) questionnaire (1), and disease activity by the DAS28 score. Statistics: Data are presented as mean, standard deviation, median, range and number and percentage. For comparison between groups non parametric statistic was used. The Spearman9s correlation coefficient was used to analyse the associations between shoulder muscle strength and other assessments <h3>Results</h3> Patients showed significantly (p&lt;0.0001) impaired shoulder muscle strength, shoulder-arm movement, and shoulder pain compared to the reference group. Patients shoulder muscle strength was approximately 65% of the results observed in the reference group. Activity limitations related to the shoulder, arm and hand (DASH) were significantly (p&lt;0.0001) higher in the patient group compared to the reference group and indicates limitations in daily activities for the patients. <h3>Conclusions</h3> Patients with early RA were found to have impaired shoulder function compared to age-matched subjects. Especially the shoulder muscle strength was reduced to 65% in the patient group. Shoulder muscle strength was found to be associated with activity limitations (DASH) implying that screening and monitoring of shoulder function, emphasising the shoulder muscle strength, should be initiated from disease onset. <h3>References</h3> Hudak PL, Amadio PC, Bombardier C. Development of an upper extremity outcome measure: the DASH (disabilities of the arm, shoulder and hand) [corrected]. The Upper Extremity Collaborative Group (UECG). Am J Ind Med. 1996 Jun;29(6):602-8. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4988
AB0584 Clinical Features of Patients with Henoch-SchÖNlein Purpura
Authors: J. Loricera, V. Calvo-Río, C. Mata, L. Martín, F. Ortiz-Sanjuán, M. Santos-Gόmez, L. Άlvarez, M.C. González-Vela, D. González-Lamuño, J. Rueda-Gotor, H. Fernández-Llaca, M.A. González-Lόpez, S. Armesto, E. Peirό, M. Arias, M.A. González-Gay, R. Blanco
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> The severity of clinical features and the outcome in the different series of patients with Henoch-Schönlein Purpura (HSP) shows great variability, probably due to selection-bias. <h3>Objectives</h3> Our aim was to establish the actual clinical spectrum of HSP in all age groups using an unselected and wide series of patients diagnosed at a single center. <h3>Methods</h3> For this purpose, we performed a retrospective review of 417 patients classified as having HSP according to the criteria proposed by Michel et al.<sup>1</sup> <h3>Results</h3> From this series of 417 patients, 240 were men and 177 women with a median age at the time of disease diagnosis of 7.5 years (interquartile range-IQR: 5.3-20.1). Three-quarters of them were children or young people 20 years old and younger (n=315) and a quarter (n=102) were adults. The most frequent precipitating events were a previous infection (38%), usually an upper respiratory tract infection, and/or drug intake (18.5%) shortly before the onset of the vasculitis. At disease onset the most common manifestations were skin lesions (55.9%), nephropathy (24%) gastrointestinal involvement (13.7%), joint symptoms (9.1%), and fever (6.2%). Cutaneous involvement occurring in all the cases, mainly purpuric skin lesion, was the most common manifestations when the vasculitis was fully established, followed by gastrointestinal (64.5%), joint (63.1%), and renal involvement (41.2%).The main laboratory data were leukocytosis (36.7%), anemia (8.9%) and increased of serum IgA levels (31.7%). The most frequent therapies used were corticosteroids (35%), nonsteroidal anti-inflammatory drugs (14%), and cytotoxic agents (5%). After a median follow-up of 12 (IQR: 2-38) months, complete recovery was observed in most cases (n=346; 83.2%) while persistent, usually mild, nephropathy was observed in 32 (7.7%) cases. Relapses were observed in almost a third of patients (n=133; 31.9%). <h3>Conclusions</h3> In conclusion, although HSP is a typical vasculitis affecting children and young people, it is not uncommon in adults. The prognosis is favorable in most cases depending mostly on renal involvement. <h3>References</h3> Michel BA, Hunder GG, Bloch DA, Calabrese LH. Hypersensiviti vasculitis and Henoch-Schönlein purpura: a comparison between the two disorders. J Rheumatol. 1992; 19:721-728. <h3>Acknowledgements</h3> This study was supported by a grant from "Fondo de Investigaciones Sanitarias" PI12/00193 (Spain). This work was also partially supported by RETICS Programs, RD08/0075 (RIER) and RD12/0009/0013 from "Instituto de Salud Carlos III" (ISCIII) (Spain). <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4358
O119 IN VIVO INHIBITION OF HBV ANTIGENEMIA AND VIREMIA BY ANTISENSE OLIGONUCLEOTIDES
Authors: G. Billioud, M. Carrillo, D. Gao, A. Kim, M.L. McCaleb, J. Crosby, R. Hamatake, Z. Hong, E. Swayze, S. Wieland
Journal: Journal of Hepatology (2014)
Effective Targeting Of The P53/MDM2 Axis In Preclinical Models Of Infant MLL-Rearranged Acute Lymphoblastic Leukemia
Authors: Richard B Lock, Jennifer Richmond, Laura High, Hernan Carol, Kathryn Evans, Agnes M. Mendomo, Raushan T. Kurmasheva, Peter J. Houghton, Malcolm A. Smith
Journal: Blood (2013)
P58 HUMAN CHOLANGIOCARCINOMA (CCA) AND CCA CANCER STEM CELLS (CSCS) ARE HIGHLY SENSITIVE TO THE ANTIPROLIFERATIVE EFFECTS OF PI3-KINASE INHIBITORS
Authors: A. Fraveto, A. Torrice, M.C. Bragazzi, A. Renzi, G. Carpino, F. Giuliante, A.M. DeRose, G. Grazi, V. Cardinale, P. Onori, A. Franchitto, C. Napoletano, R. Gentile, E. Gaudio, D. Alvaro
Journal: Journal of Hepatology (2014)
NON-DIPPING VERSUS NOCTURNAL HYPERTENSION: IMPROVING DETECTION OF PRECLINICAL ORGAN DAMAGE IN HYPERTENSION
Authors: Emmanuel Androulakis, Nikolaos Papageorgiou, Evaggelos Chatzistamatiou, Spyridon Papaioannou, Andreas Synetos, George Latsios, Ioannis Kallikazaros, Christodoulos Stefanadis, Dimitris Tousoulis
Journal: Journal of the American College of Cardiology (2015)
Intraductal Ultrasonography of the Bile Duct System
Authors: K. Tamada, K. Inui, J. Menzel
Journal: Endoscopy (2001)

The ultrasonic miniprobe is an ideal instrument for insertion into fluid-filled tubular structures such as the bile duct system which are only slightly larger in diameter than the miniprobe itself. Possible clinical indications for miniprobe ultrasonography of the biliary tract are (i) bile duct strictures, and (ii) choledocholithiasis. The technique of intraluminal ultrasonographic imaging is called “intraductal ultrasonography” (IDUS) [[1] [2] [3] [4] [5] [6] [7] [8] [9] [10] ].
PTH-038 Albumin As A Plasma Expander During Large Volume Paracentesis: Are We Following The Guidelines?: Abstract PTH-038 Table 1
Authors: G Goodchild, C Skinner, A Dias
Journal: Gut (2014)

<h3>Introduction</h3> Ascites is a major complication of cirrhosis occurring in more than 50% of patients within 10 years. Tense ascites is treated with large volume paracentesis (LVP) with human albumin solution (HAS) as a plasma expander. National and International guidelines recommend that cirrhotic patients undergoing LVP (&gt;5 l) should have 8 g of HAS per litre of ascites drained. This equates to 1 unit of 20% HAS per 2.5 l of ascites drained. HAS is not recommended for non-cirrhotic ascites or small volume paracentesis (SVP), where &lt;5 l of ascites is drained. Our aim was to see if local practice followed guidelines. <h3>Methods</h3> We conducted an audit of all paracenteses occurring in a London district general hospital between January 2012 and October 2013. We included day unit patients and inpatients undergoing paracentesis. We reviewed medical notes, prescription charts and nursing records, including cases with suitable documentation. <h3>Results</h3> Sixteen patients had a total of 48 drainage episodes between them, of which 9 were male and median age was 71 years (range 45–93 years). Eleven patients had cirrhosis and 5 had non-hepatic malignancy. Table 1 demonstrates that there were 36 paracentesis episodes in cirrhotic patients where LVP was carried out with a median of 4 units of HAS given per drainage. On the other 12 occasions HAS did not need to be given. In 20/36 cases at least 2.5 l of ascites was drained for each unit of HAS given. In the 16 other cases of LVP in the cirrhotic patients, HAS was overprescribed with a total of 19 units being given unnecessarily in this group. In total 25 units of HAS were given to patients undergoing small-volume paracentesis and those with malignant ascites. The cost per unit of HAS is £29, thus potentially £1276 could have been saved if guidelines had been followed. There were no complications associated with drain insertion nor was there any hypotension, acute kidney injury, or electrolyte disturbance related to HAS infusion. <h3>Conclusion</h3> Albumin is often inappropriately prescribed to patients with malignant ascites and those undergoing small volume paracentesis. Of the paraceteses where HAS was indicated, 16/36 (44%) were overprescribed albumin. This has unnecessary cost implications as well as potential health risks due to the hyperoncotic properties of HAS. We conclude that reducing HAS usage by following guidelines during LVP would reduce costs without compromising patient safety. <h3>Reference</h3> Runyon B Management of Adult Patients with Ascites due to Cirrhosis: An Update. AASLD Practice Guidelines, 2012. <h3>Disclosure of Interest</h3> None Declared.
Imaging Osteomyelitis With Tc-99m-Labeled Antigranulocyte Antibody Fab′ Fragments
Authors: Thomas Von Rothenburg, Josef Schaffstein, Jörn Ludwig, Dirk Vehling, Odo Köster, Gebhard Schmid
Journal: Clinical Nuclear Medicine (2003)

Purpose The purpose of this study was to evaluate the diagnostic value of Tc-99m-labeled antigranulocyte antibody fragments in the diagnosis of osteomyelitis. Materials and Methods Thirty immunoscintigrams were evaluated retrospectively with 740 MBq (20 mCi) Tc-99m-labeled antigranulocyte antibodies. The final diagnoses were confirmed by histology, magnetic resonance imaging, computed tomography, and clinical follow-up. Results In the retrospective analysis, 20 of 30 patients (67%) demonstrated a true-positive result. Three of 30 patients (10%) had a false-positive result. A false-negative result was found in a diabetic patient with a perforating ulcer of the foot. Six of 30 patients had a true-negative result. A high sensitivity of 95%, a relatively high specificity of 67%, and a high diagnostic accuracy of 86% were present in this study. Conclusion Tc-99m labeled monoclonal antibody–Fab′ fragments are suitable for the detection of osteomyelitis. Its clinical application is simple. Its use guarantees a reliable and accurate diagnostic result just 1 to 2 hours after injection, making a late scan unnecessary. Coxarthrosis or hyperostosis can lead to false-positive results. A perforating ulcer of the foot may result in a false-negative conclusion.
Abstract 1740: SATB2 localizes to mitotic microtubules and centrosome of cell cycles and regulates G1 phase cell cycle via proteosomal-dependent CDK2 in SKOV-3 ovarian cancer cells.
Authors: Eun Ah Sin, Eun J. Sohn, Ji Hoon Jung, Duckgue Lee, Bonglee Kim, Duck-Beom Jung, Ji-Hyun Kim, Hyo-Jeong Lee, Sung Hoon Kim
Journal: Cancer Research (2013)

Abstract Though special AT-rich sequence-binding protein 2 (SATB2) is known as a transcriptional regulator of skeletal development and osteogenic differentiation, the underlying role of SATB2 still remains unclear. In the present study, we found that SATB2 localized to the mitotic microtubules, centrosome and midbodies in mitotic cells with α-tubulin. SATB2 knockdown by siRNA transfection reduced the cell viability, and increased the number of ethidium homodimer positive stained cells in SKOV3 ovarian cancer cells. Consistently, cell cycle analysis revealed that SATB2 knockdown accumulated G1 arrest and downregulated the cyclin-dependent kinase 2 (CDK2) expression by western blotting, while immunofluorescence assay revealed that CDK2 and SATB2 were co-localized in SKOV3 cells. Furthermore, proteosomal inhibitor MG132 treatment reversed the downregulation of CDK2 induced by SATB2 knockdown in SKOV3 cells. Overall, our findings suggest that SATB2 regulates the mitosis and G1 phase cell cycle via proteosomal ubiquitination in SKOV3 ovarian cancer cells. Citation Format: Eun Ah Sin, Eun J. Sohn, Ji Hoon Jung, Duckgue Lee, Bonglee Kim, Duck-Beom Jung, Ji-Hyun Kim, Hyo-Jeong Lee, Sung Hoon Kim. SATB2 localizes to mitotic microtubules and centrosome of cell cycles and regulates G1 phase cell cycle via proteosomal-dependent CDK2 in SKOV-3 ovarian cancer cells. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1740. doi:10.1158/1538-7445.AM2013-1740
O152 THE SPLICING FACTOR SLU7 IS ESSENTIAL FOR THE PRESERVATION OF LIVER DIFFERENTIATION, METABOLIC FUNCTION AND QUIESCENCE
Authors: M. Elizalde, R. Urtasun, M. Azkona, M.U. Latasa, S. Goñi, O. Garcia-Irigoyen, I. Uriarte, V. Segura, M. Collantes, M. Di Scala, A. Lujambio, J. Prieto, M.A. Ávila, C. Berasain
Journal: Journal of Hepatology (2014)
Loculated Pericardial Effusion Detected on Blood Pool Bone Imaging
Authors: PHILIP T. MINSHEW, FRANK V. SCHRAML, GUILLERMO OLIVOS, KEITH T. CHESSER, EUGENE D. SILVERMAN
Journal: Clinical Nuclear Medicine (1999)

The authors evaluated an 80-year-old man with congestive heart failure and Staphylococcus aureus sepsis. A three-phase bone scan was performed to identify possible osteomyelitis of the cervical spine. The blood pool images revealed a round photopenic defect within an area of diffuse pericardial uptake. This corresponded to a 5 × 7 cm pericardial mass noted on CT. A pericardial effusion also was noted. A subsequent In-111 leukocyte study showed no abnormal localization. The pericardial collection measured 6 Hounsfield units on CT and was consistent with a loculated pericardial effusion within the backdrop of a pericardial effusion.
Clinical practice Guidelines: quality of colonoscopy in colorectal cancer screening
Authors: R. Jover, M. Herráiz, O. Alarcón, E. Brullet, L. Bujanda, M. Bustamante, R. Campo, R. Carreño, A. Castells, J. Cubiella, P. García-Iglesias, A. Hervás, P. Menchén, A. Ono, A. Panadés, A. Parra-Blanco, M. Pellisé, M. Ponce, E. Quintero, J. Reñé, A. Sánchez del Río, A. Seoane, A. Serradesanferm, A. Soriano Izquierdo, E. Vázquez Sequeiros
Journal: Endoscopy (2012)

Collecting the evidence about the quality of colonoscopy screening for colorectal cancer (CRC) in order to serve as a tool for screening programs, endoscopy units and endoscopists that perform screening colonoscopies. Defining and establishing quality indicators and minimum requirements based on available evidence that endoscopy units and endoscopists involved in CRC screening programs should meet. Providing evidence about procedures that may improve the quality of colonoscopy.
Can developmental psychology provide a blueprint for the study of adult cognition?
Authors: Arthur B. Markman
Journal: Behavioral and Brain Sciences (2011)

Abstract In order to develop sophisticated models of the core domains of knowledge that support complex cognitive processing in infants and children, developmental psychologists have mapped out the content of these knowledge domains. This research strategy may provide a blueprint for advancing research on adult cognitive processing. I illustrate this suggestion with examples from analogical reasoning and decision making.